Alexander Ehlgen - Profile and Investment Details

Investor Profile

Alexander Ehlgen is a Venture Capital, Corporate Venture Capital, Investor based in Biberach, Baden-Württemberg, Germany with a diverse investment portfolio that includes companies such as Aignostics, T3 Pharmaceuticals, Dopavision, Topas Therapeutics, Actym, eTheRNA immunotherapies, STAT-Dx, Rinri Therapeutics, Rigontec, Hookipa Pharma, Tacalyx, NBE-Therapeutics, Aelin Therapeutics, Okairos, ImCheck Therapeutics, Wellth, T-knife, Brainomix, Tacalyx GmbH, Obulytix, Acousia Therapeutics, Rgenta Therapeutics, DiogenX, Cardior Pharmaceuticals, C-mo Medical Solutions, Delonix Bioworks, Bodyport, Ruipeng Pet HealthcareLantheus Medical Imaging, Metabomed, ArmaGen Technologies, POINT Biomedical Corporation, Rewind Therapeutics, HepaRegeniX, Perfood, Eyevensys, Promethera Biosciences, Sentien Biotechnologies, Amal Therapeutics, Bristol-Myers Squibb, Vira Therapeutics, OncoMyx Therapeutics, Libra Therapeutics, Abalos Therapeutics, AgomAb Therapeutics, . Over time, Alexander Ehlgen has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Alexander Ehlgen is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Patient Care, Health Care, Research and Development, Hospitals, Wellness, Corporate Social Responsibility Management, Women Founded, Rare Diseases, Transportation, Healthcare Innovation, Chemical, Life Science, Artificial Intelligence (AI), Software, Manufacturing, Biotechnology, Consumer Health, Drug Development, Cosmetics, Market Research, Specialty Pharma, Electronic Health Records (EHR), Health and Hospital Services, Clinical Trials, Research, Licensing, Marketing, Logistics, Health Diagnostics, Innovation Management, Digital Health, Regulatory Compliance, Renewable Energy, Medical, B2B, Therapeutics, Advanced Materials, Machine Learning, Personal Health, Industrial Manufacturing, Pharmaceuticals, Acquisitions, Oncology may find it worthwhile to explore potential connections with Alexander Ehlgen, as their portfolio suggests a familiarity and interest in this area.

Understanding Alexander Ehlgen’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.